Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | PTPRF | P10586 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237586 | 0.91 | MAPT (0.70) | MAPTHIF1AMAOAMAOBCCR2 | |
| SCHEMBL11181983 | 0.91 | MAPT (0.65) | MAPTHIF1AMAOAMAOBCCR2 | |
| SCHEMBL6911275 | 0.91 | MAPT (0.59) | MAPTHIF1AMAOAMAOBCCR2 | |
| SCHEMBL1235852 | 0.89 | MAPT (0.68) | MAPTHIF1AMAOAMAOBCCR2 | |
| SCHEMBL3397911 | 0.89 | MAPT (0.62) | MAPTHIF1AMAOAMAOBCCR2 | |
| SCHEMBL1021060 | 0.84 | MAPT (0.56) | MAPTHIF1AMAOAMAOBCCR2 | |
| SCHEMBL1238056 | 0.83 | MAPT (0.55) | MAPTHIF1AMAOAMAOBCCR2 | |
| SCHEMBL14763707 | 0.80 | MAPT (0.57) | MAPTHIF1ACCR2 | |
| SCHEMBL10975426 | 0.80 | — | — | |
| SCHEMBL2569326 | 0.79 | MAPT (0.51) | MAPTHIF1AMAOAMAOBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4515720-A | Method of synthesizing a late-stage intermediate to 11-deoxydaunorubicin and 11-deoxyadriamycin, and two precursors to the object intermediate | OREGON GRADUATE CENTER FOR STUDY & RESEARCH (US) | 1985-05-07 | — | — | US | claimed |
| EP-2622051-A1 | 4,4-DIMETHYL-DECAL-1-ONE OR -1-OL DERIVATIVES AS PERFUMING INGREDIENTS | Firmenich SA (CH) | 2013-08-07 | — | — | EP | disclosed |
| US-8263764-B2 | IL-12 Modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| WO-2012041820-A1 | 4,4-DIMETHYL-DECAL-1-ONE OR -1-OL DERIVATIVES AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2012-04-05 | — | — | WO | disclosed |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | US | disclosed |
| US-7863270-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100189672-A1 | DECALINE DERIVATIVES AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20060281711-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-12-14 | — | — | US | disclosed |
| WO-2006124662-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-4543428-A | Production of a hexahydronaphthalenone compound | OREGON GRADUATE CENTER FOR STUDY & RESEARCH (US) | 1985-09-24 | — | — | US | disclosed |
| US-4543428-A | Production of a hexahydronaphthalenone compound | OREGON GRADUATE CENTER FOR STUDY & RESEARCH (US) | 1985-09-24 | — | — | US | disclosed |
| US-4515720-A | Method of synthesizing a late-stage intermediate to 11-deoxydaunorubicin and 11-deoxyadriamycin, and two precursors to the object intermediate | OREGON GRADUATE CENTER FOR STUDY & RESEARCH (US) | 1985-05-07 | — | — | US | disclosed |
| US-4499289-A | ANTIATHEROSCLEROSIS | G. D. SEARLE & CO. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0111261-A2 | Octahydronapthalenes | G.D. Searle & Co. (US) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281711-A1 | IL-12 modulatory compounds | IL2, IL4, IL15 | MAPT 3832/4885HIF1A 230/4885MAOA 2199/4885 |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IL15 | MAPT 3832/4885HIF1A 230/4885MAOA 2199/4885 |
| US-20100189672-A1 | DECALINE DERIVATIVES AS PERFUMING INGREDIENTS | DECR1, CHRM5, CHRNA7 | MAPT 1419/4885HIF1A 3203/4885MAOA 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.